** Shares of Telix Pharmaceuticals rise as much as 7.4% to A$25.79, their biggest gain since Sept. 20, 2024
** Stock hits highest level since Dec. 18, 2024 ** The biopharmaceutical co records revenue of $517 mln in FY, beating its forecast of $490 mln to $510 mln
** Co reports 55% y-o-y growth in full-year revenue ** Stock is among the top 10 performers on ASX 200 benchmark
** Shares gained 144.1% in 2024
(Reporting by Jasmeen Ara Shaikh in Bengaluru) ((mailto:Jasmeenaraislam.shaikh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。